INSUBCONTINENT EXCLUSIVE:
Share prices of Glenmark Pharmaceuticals rose over 3 per cent early
Monday as its subsidiary Glenmark Arzneimittel secured marketing
authorisation for a dry powder inhaler in Germany
Accuhaler.
Fluticasone/Salmeterol DPI is a combination product for the treatment of asthma and chronic obstructive pulmonary disease (COPD)
respiratory products segment
Achin Gupta, Executive Vice-President and Business Head of Europe and Latin America, Glenmark Pharmaceuticals.
Glenmark had entered into a
strategic development and licensing agreement with Celon Pharma SA (Celon) in 2015 to develop and market generic Fluticasone/Salmeterol DPI
in 15 European countries.
The company has already launched this product in Denmark, Sweden and Norway.
According to IQVIA data,
Fluticasone/Salmeterol dry powder inhaler (DPI) had sales of $844 million in Europe in the 12 months to March 2018.
The scrip was 3.48 per
cent up at Rs 707 at around
9.30 am
The BSE Sensex was down 108 points, or 0.28 per cent, at 38,281 at around the same time.
